TP53 and B-cell chronic lymphocytic leukemia: Overall, the estimated 36.6% discontinuation rate that we observed at 24 months in our study, along with the 82.6% survival rate and 76.6% PFS rate confirm that first-line treatment with ibrutinib is effective in high-risk CLL with TP53 aberrations.